Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 50 Women only

Investigating the role of endothelin-1 in blood vessel function after gestational diabetes

Official title: Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

Run by University of Iowa · NCT06547619 · Data updated 2026-11-12

This study is testing how a substance called endothelin-1 affects blood vessel function in women who had gestational diabetes to see if insulin can help improve their heart health after pregnancy.

More Gestational Diabetes trials

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 50 Years
SexWomen only
Enrollment40 (estimated)
SponsorUniversity of Iowa
Academic / other
Locations1 site (Iowa City, Iowa)
StatusRecruiting
StartedOctober 1, 2024
Main results expectedSeptember 30, 2026
Study endsMay 2027
Registry record updatedOctober 29, 2026
Trial IDNCT06547619 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women who have had a pregnancy within the last five years, particularly those diagnosed with gestational diabetes.

Probably not a fit

Patients with current hypertension, metabolic diseases, or those who are currently pregnant will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines how endothelin-1, a potent vasoconstrictor, affects microvascular function in women who have experienced gestational diabetes mellitus (GDM). It aims to understand the mechanisms behind persistent vascular dysfunction that can occur postpartum, despite the resolution of insulin resistance. The study will involve administering insulin aspart to assess its impact on endothelial function in this population. By focusing on women within five years postpartum, the research seeks to uncover critical insights into cardiovascular risk following GDM.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of cardiovascular risks in women with a history of gestational diabetes.

How similar studies have gone: While the association between GDM and cardiovascular risk is established, this specific investigation into endothelin-1's role in microvascular dysfunction is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
INCLUSION CRITERIA

* history of pregnancy within 5 years of the study visit
* had healthy pregnancy OR had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes.

EXCLUSION CRITERIA

* skin diseases,
* current tobacco or electronic cigarette/vape pen use,
* diagnosed or suspected hepatic or metabolic disease including diabetes,
* statin or other cholesterol-lowering medication,
* current antihypertensive medication,
* history of preeclampsia or gestational hypertension
* current hypertension,
* current pregnancy,
* body mass index \<18.5 kg/m2,
* allergy to materials used during the experiment.(e.g. latex), known allergies to study drugs.

Where it's running

  • University of Iowa
    Iowa City, Iowa, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.